Health insurance companies are spending billions of dollars to make sure the doctors and other medical-care providers they work with have the tools they need to move from fee-for-service medicine to value-based care and population health.
Exact Sciences shares were cut to neutral today by Goldman Sachs.
Insurance companies are pushing more aggressively than ever away from paying doctors and hospitals with fees for service, and that means more revenue left on the table.
Castlight Health, Inc.'s shares are tumbling following guidance for 2015 that misses Wall Street estimates.
Express Scripts offers five key takeaways on drug spending tied to Obamacare exchange plans.
Gilead Sciences stock soars in January after it goes on the offensive to protect its hepatitis C product portfolio. Find out if Gilead shares can head even higher in the coming months.
These factors will make the difference for Gilead Sciences when it announces Q4 results on Feb. 3.
A critical ruling by the Supreme Court this June on the legality of federal subsidies could affect millions of Obamacare enrollees. Find out, based on a recently released analysis, what a ruling in favor of the plaintiff could mean for overall enrollment and premium prices in 2016.
The PEG ratio is a temptingly simple valuation tool. But does it really work? Read all about it.
Gilead Sciences, Amgen, and Biogen Idec could be the best biotech stocks to buy.